Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2005

View Archived Issues

CHIR-12.12 active against human multiple myeloma in preclinical studies

Pharmacological profile of KSR-AS-214231 reported

Promising data on CHIR-258 in multiple myeloma

Clinical evidence supports the use of bortezomib in multiple myeloma

Oncolytic activity of TPI-287 in drug-resistant tumors

In vivo antitumor efficacy of CHR-2797

Herceptin improves disease-free survival in early breast cancer

Phase III trial begins with aztreonam lysinate for inhalation in cystic fibrosis

Phase II trial studies SomatoKine for type A extreme insulin resistance

CG-0070 enters phase I trial for recurrent bladder cancer

OncoGenex Technologies inlicenses Hsp27 inhibitor rights

Alzheimer's Disease Cooperative Study selects Allon Therapeutics program

Biovitrum completes acquisition of Cambridge Biotechnology

GPC Biotech and Ingenium receive German funding

Two European trials begin for AP-23573 in advanced cancers

Glenmark and Teijin Pharma sign agreement for PDE4 inhibitor in Japan

SPA agreement for phase III CoFactor study in metastatic colorectal cancer

NIH funding for Arteriocyte's stem cell testing for ischemic heart disease

Asoprisnil found to prolong menstrual cycle in healthy premenopausal women

Preliminary data support the use of alglucosidase alfa in the treatment of Pompe disease

Update on the efficacy of ISA-247 in psoriasis

Good cardiovascular profile reported for avanafil in male volunteers

Phase I data on a fluoruoracil/UCN-01 combination in advanced cancer

Recent Wyeth patents disclose novel 5-HT6 receptor ligands

Novel antiarthritic agents imparted in recent patent literature

New treatments claimed for pruritus and other allergic and dermatological disorders

CONCEPT trial shows superiority of stable-dose salmeterol/fluticasone in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...